About Amgen
Amgen is a company based in Thousand Oaks (United States) founded in 1980. The company has 28,000 employees as of December 31, 2024. Amgen has completed 26 acquisitions, including Abgenix, Alantos Pharmaceuticals and Amgen Astellas BioPharma. Amgen offers products and services including Biologic Medicines and Clinical Trials Services. Amgen operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Thousand Oaks, United States
- Employees 28000 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amgen Inc.
-
Annual Revenue
$33.23 B (USD)18.64as on Dec 31, 2024
-
Net Profit
$4.09 B (USD)-39.11as on Dec 31, 2024
-
EBITDA
$13.9 B (USD)6.45as on Dec 31, 2024
-
Latest Funding Round
$175.46 M (USD), Post-IPO
Mar 12, 2012
- Investors
-
Employee Count
28000
as on Dec 31, 2024
-
Investments & Acquisitions
Abgenix
& 25 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Amgen
Amgen is a publicly listed company on the NASDAQ with ticker symbol AMGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Amgen
Amgen offers a comprehensive portfolio of products and services, including Biologic Medicines and Clinical Trials Services.
Treatments for serious illnesses through biologic innovations.
Platforms for optimizing and conducting medical trials worldwide.
People of Amgen
Unlock access to complete
Unlock access to complete
Software Development Team
208 people
Leadership Team
193 people
Sales and Marketing
82 people
Data Analysis and Operations Team
73 people
Senior Team
66 people
Operations Team
64 people
Product Management Team
55 people
Scientific Team
34 people
Unlock access to complete
Funding Insights of Amgen
Investors in Amgen
Amgen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Amgen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amgen
Amgen has strategically engaged in corporate development activities, having acquired 26 companies. Notable acquisitions include Abgenix, Alantos Pharmaceuticals and Amgen Astellas BioPharma.
Investment portfolio details for Amgen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops precision medicines for cancer using expert partnerships and drug pipelines.
|
Locked | Locked | 2020 | Locked | |
|
Prostaglandin-degrading enzyme inhibitors are developed for inflammatory bowel disease treatment.
|
Locked | Locked | 2017 | Locked | |
|
IL-15 monoclonal antibodies for celiac disease therapies are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Amgen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Amgen
Detailed financials for Amgen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amgen Comparisons
Peer comparison for Amgen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amgen
Amgen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Amgen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amgen
Complete news archive for Amgen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amgen
Amgen was founded in 1980 and raised its 1st funding round 30 years after it was founded.
Amgen is headquartered in Thousand Oaks, United States. It is registered at Thousand Oaks, California, United States.
Robert Bradway is the current CEO of Amgen.
As of Dec 31, 2024, the latest employee count at Amgen is 28,000.
Annual revenue of Amgen is $33.23B as on Dec 31, 2024.
Amgen was founded in 1980 in Thousand Oaks, United States, within the biotechnology sector. Pharmaceutical products are developed to address multiple diseases through advances in cellular and molecular biology. Human therapeutics are manufactured and marketed, with operations centered on hematology, oncology, and inflammation. In 2022, annual revenues of 26.32 billion were achieved, alongside a net profit of 6.55 billion.
Amgen's top competitors include Merck, Roivant Sciences and AbbVie.
Amgen offers Biologic Medicines and Clinical Trials Services.
Yes, Amgen is publicly traded on NASDAQ under the ticker symbol AMGN.
Amgen has made 26 acquisitions, including Abgenix, Alantos Pharmaceuticals, and Amgen Astellas BioPharma.
Amgen has 1 investor. Key investors include European Union.
The ticker symbol of Amgen is AMGN on NASDAQ.